| Code | CSB-RA005034MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody disclosed in US20150337048A1, targeting CDH1 (E-cadherin), a calcium-dependent cell adhesion molecule critical for maintaining epithelial tissue integrity. CDH1 mediates homophilic cell-cell adhesion and plays essential roles in tissue architecture, cell polarity, and intracellular signaling pathways. Loss of CDH1 function is strongly associated with epithelial-mesenchymal transition, a key process in cancer metastasis, and germline mutations in CDH1 are causative for hereditary diffuse gastric cancer syndrome. Reduced E-cadherin expression is observed across multiple carcinomas, including gastric, breast, colorectal, and ovarian cancers, making it a significant marker in cancer research.
This biosimilar antibody provides researchers with a cost-effective alternative for investigating CDH1 expression patterns, localization, and functional roles in cellular adhesion mechanisms and tumor biology. It serves as a valuable tool for studies examining epithelial integrity, developmental biology, cancer progression, and metastatic processes.
There are currently no reviews for this product.